Among patients with multiple myeloma who received anti-CD38 monoclonal antibody-based treatment the relative risk for infection was 1.27, with a 28% incidence of severe infection. Consequently, we describe the importance of surveillance and prophylactic strategies across our studied patient population.
All Keywords
【저자키워드】 monoclonal antibodies, infections, Multiple myeloma, daratumumab, Isatuximab,
【저자키워드】 monoclonal antibodies, infections, Multiple myeloma, daratumumab, Isatuximab,